Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Maky
Zanganeh, DDS, MBA, has been appointed as Co-Chief Executive
Officer & President, effective immediately. Dr. Zanganeh
was formerly the Company’s Chief Operating Officer, having served
in that capacity since she joined the Company as an employee in
November 2020, and remains a member of the Company’s Board of
Directors.
“Maky defines what it means to be a great
leader,” said Robert W. Duggan, Executive Chairman and Chief
Executive Officer of Summit. “We have assembled a world-class
leadership team here at Summit and have guided a group of
accomplished executives into the next chapter of our growth. As we
seek to expand our pipeline through business development
activities, as well as chart the path forward with our current
pipeline drug candidates, there is no one, exemplified by Maky’s
past successes, that is better prepared to lead us through this
journey. I am proud to serve alongside Maky and partner with her
expertise as the co-leaders of this organization built with the
purpose of improving the condition of overall human health.”
Prior to joining Summit, Dr. Zanganeh founded
Maky Zanganeh and Associates in 2015, and from 2008 to 2015,
she held multiple leadership positions at Pharmacyclics, Inc.,
culminating in her role as Chief Operating Officer. As COO of
Pharmacyclics, she oversaw all clinical development, regulatory,
research, and commercial functions in addition to all
business-related matters. Dr. Zanganeh played a key role
in the over $1 billion collaboration and license deal for
ibrutinib with Janssen Biotech, Inc. in 2011, and the subsequent
sale of Pharmacyclics to AbbVie Inc. for $21 billion in
2015. She is currently a board member for Pulse Biosciences,
Inc. Dr. Zanganeh received her DDS from the Louis Pasteur
University (France) and her MBA from Schiller International
University (France).
Earlier this year, Dr. Zanganeh was an honored
speaker at the United Nations’ 7th Anniversary of the February 11
Global Movement celebrating women and girls in science. Dr.
Zanganeh was also named a “Top 10 Most Influential COOs of 2021” by
Industry Era magazine. She earned the Fierce Biotech “Top Women in
Biotech 2013” award and was a finalist for the Ernst & Young
“Entrepreneur of the Year” award in 2013. She is also a published
author, recently releasing her book entitled, The Magic of
Normal.
“I am truly honored to be elevated to the Co-CEO
role at Summit,” stated Dr. Zanganeh. “The trust shown in Bob
and me by many of our former executives at past adventures to join
us at Summit, combined with our new talented leaders working with
us for the first time, speaks volumes as to the impact we can
accomplish for patients. Our mission-driven culture to always
consider how we can help patients in every decision that we make
will ultimately guide us to making a meaningful difference in
resolving high unmet needs in oncology and infectious diseases. I
am humbled by the opportunity to co-lead our impressive group of
accomplished executives and teammates as we seek to expand our
pipeline and achieve this goal.”
Summit Therapeutics’ Mission StatementTo
build a viable, long-lasting health care organization that assumes
full responsibility for designing, developing, trial execution and
enrollment, regulatory submission and approval, and successful
commercialization of patient, physician, caregiver, and
societal-friendly medicinal therapy intended to: improve
quality of life, increase potential duration of life, and resolve
serious medical healthcare needs. To identify and control promising
product candidates based on exceptional scientific development and
administrational expertise, develop our products in a rapid,
cost-efficient manner, and to engage commercialization and/or
development partners when appropriate.
We accomplish this by building a team of world
class professional scientists and business administrators that
apply their experience and knowledge to this mission. Team Summit
exists to pose, strategize, and execute a path forward in medicinal
therapeutic health care that places Summit in a well-deserved, top
market share, leadership position. Team Summit assumes full
responsibility for stimulating continuous expansion of knowledge,
ability, capability, and well-being for all involved stakeholders
and highly-valued shareholders.
About Summit TherapeuticsSummit was
founded in 2003 and our shares are listed on the Nasdaq Global
Market (symbol ‘SMMT’). We are headquartered in Menlo Park,
California, and we have additional offices in Oxford, UK, and
Cambridge, UK.
For more information, please visit
https://www.summittxinc.com and follow us on Twitter
@summitplc.
Contact Summit Investor Relations:
Dave GancarzHead of Stakeholder Relations &
Corporate Strategydavid.gancarz@summitplc.com
General Inquiries:
investors@summitplc.com
Summit Forward-looking Statements
Any statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the clinical and preclinical
development of the Company’s product candidates, the therapeutic
potential of the Company’s product candidates, the potential
commercialization of the Company’s product candidates, the timing
of initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing
approvals, the impact of the COVID-19 pandemic on the Company’s
operations and clinical trials, potential acquisitions and other
statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "would," and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including the results of our evaluation of the underlying
data in connection with the topline results of our Phase III
Ri-CoDIFy study evaluating ridinilazole, the outcome of discussions
with regulatory authorities, including the Food and Drug
Administration, the uncertainties inherent in the initiation of
future clinical trials, availability and timing of data from
ongoing and future clinical trials, the results of such trials, and
their success, and global public health crises, including the
coronavirus COVID-19 outbreak, that may affect timing and status of
our clinical trials and operations, whether preliminary results
from a clinical trial will be predictive of the final results of
that trial or whether results of early clinical trials or
preclinical studies will be indicative of the results of later
clinical trials, whether business development opportunities to
expand the Company’s pipeline of drug candidates, including without
limitation, through potential acquisitions of, and/or
collaborations with, other entities occur, expectations for
regulatory approvals, laws and regulations affecting government
contracts and funding awards, availability of funding sufficient
for the Company’s foreseeable and unforeseeable operating expenses
and capital expenditure requirements and other factors discussed in
the "Risk Factors" section of filings that the Company makes with
the Securities and Exchange Commission. Any change to our ongoing
trials could cause delays, affect our future expenses, and add
uncertainty to our commercialization efforts, as well as to affect
the likelihood of the successful completion of clinical development
of ridinilazole. Accordingly, readers should not place undue
reliance on forward-looking statements or information. In addition,
any forward-looking statements included in this press release
represent the Company’s views only as of the date of this release
and should not be relied upon as representing the Company’s views
as of any subsequent date. The Company specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Sep 2023 to Sep 2024